Priority Review Granted for Ripretinib
Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).